Clinical trials
Pancreatitis clinical trials
Below are recruiting pancreatitis clinical trials, each written for real people, not researchers. We’re tracking 1,044 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06655051Recruiting
Plastic versus metal stent for bile duct blockage from chronic pancreatitis
This study compares two types of stents (plastic vs. metal) to see which works better for treating bile duct narrowing caused by chronic pancreatitis. If you have a bile duct blockage from chronic pancreatitis, you may be eligible.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06655233Recruiting
Exploring gut bacteria in pancreatic cancer tumors
This trial studies bacteria found inside pancreatic tumors to see if they can help diagnose or predict the course of the disease. You may be eligible if you have a suspected pancreatic cancer and need a special biopsy (EUS-FNB).
Hunan, HunanAges 18–80 - NCT06662006RecruitingPhase 2
Nal-IRI chemo with immunotherapy and radiation for pancreatic cancer
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Nanjing, JiangsuAges 18–75 - NCT06663072RecruitingPhase 1
Testing fulvestrant plus lutetium therapy for advanced pancreatic neuroendocrine tumors
This trial tests a new combination of two drugs: lutetium-177 DOTATATE (a type of radiation therapy that targets tumor cells) and fulvestrant (a hormonal therapy). It is for people with advanced pancreatic neuroendocrine tumors that have grown despite previous treatments.
Chicago, IllinoisAges 18 years+ - NCT06691425Recruiting
Radiation for pancreatic cancer that can't be removed
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
Edegem, AntwerpenAges 18 years+ - NCT06705335Recruiting
Pancreatic cancer study: looking at convertase enzymes
This study collects tissue samples from people with pancreatic cancer to study convertase enzymes. It may help us understand how these enzymes affect the disease.
BordeauxAges 18 years+ - NCT03684278RecruitingPhase 2
Infliximab for new acute pancreatitis patients in the first 36 hours
This trial tests infliximab (an anti-inflammatory medicine) versus placebo to see if it improves outcomes in adults with newly diagnosed acute pancreatitis. It is designed for treatment to start within 36 hours of hospital admission.
Aberdeen, AberdeenshireAges 18–85 - NCT06714604RecruitingPhase 3
Comparing standard vs. longer chemo before pancreatic cancer surgery
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
Gothenburg, VGRAges 18–90 - NCT06736678Recruiting
Nutritional drink to reduce side effects from pancreatic cancer treatment
This trial tests a special nutritional drink (oral immunonutrition) to see if it can reduce side effects from chemotherapy and radiation in people with pancreatic cancer. It may help you feel better during treatment if you are at risk for malnutrition.
Guangzhou, GuangdongAges 18 years+ - NCT06736717RecruitingPhase 1/Phase 2
Testing onvansertib plus chemo for first-line advanced pancreatic cancer
This trial tests a new drug called onvansertib combined with standard chemotherapy (NALIRIFOX) as the first treatment for advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to see if adding onvansertib helps shrink tumors or slow the cancer better than chemo alone.
Kansas City, KansasAges 18 years+ - NCT06747481Recruiting
Predicting nerve invasion in pancreatic cancer
This study looks at two simple blood tests (neutrophil-to-lymphocyte ratio and CA 19.9) to see if they can predict whether the cancer has spread to nearby nerves in people with pancreatic cancer who have had surgery. This could help doctors plan better treatment.
Las Palmas de Gran Canaria, Las PalmasAges Any age - NCT06756074RecruitingPhase 2
Surgical glue study for Whipple surgery patients
This trial compares two ways of reconnecting the pancreas after a Whipple surgery for cancer. It tests whether using a special surgical glue (Glubran2) helps reduce leaks and improve healing.
MinyaAges 18–75 - NCT06758544RecruitingPhase 1/Phase 2
VRT106 plus chemo for resectable pancreatic cancer
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18–75 - NCT06764134Recruiting
Testing a new stapler to prevent pancreatic leaks after surgery
This trial tests a new type of stapler (AEON) used during surgery to remove the left part of the pancreas. The goal is to see if it helps reduce the risk of a leak from the pancreas after surgery.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06767813RecruitingPhase 2
Study of TQB2868, anlotinib, and chemo for first-line pancreatic cancer
This trial tests a new combination of drugs (TQB2868, anlotinib, and chemotherapy) as a first treatment for metastatic pancreatic cancer that has spread. It may help if you have not had prior treatment for advanced disease.
Zhengzhou, HenanAges 18–75 - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT06777030Recruiting
Study of exosomes in pancreatic cancer
This study looks at tiny particles called exosomes in pancreatic cancer. Researchers want to understand how exosomes may help the cancer grow, which could lead to better treatments in the future.
BolognaAges 18 years+ - NCT06782932RecruitingPhase 1/Phase 2
Vaccine and Immunotherapy for Removable Pancreatic Cancer
This trial tests two different vaccines (GVAX and a mKRAS vaccine) given before and after surgery for pancreatic cancer. Both vaccines are combined with immunotherapy drugs to help your immune system fight the cancer. The goal is to see which vaccine works better and is safe for patients whose tumors can be removed.
Baltimore, MarylandAges 18 years+ - NCT06790134Recruiting
AI-assisted pancreas ultrasound training study
This study tests whether an AI tool can help doctors perform and learn pancreatic ultrasound exams better. If you need a pancreas ultrasound, you may be able to join.
ChangshaAges 18–80 - NCT06790602RecruitingPhase 2
Cemiplimab plus gemcitabine for metastatic pancreatic cancer
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
La Jolla, CaliforniaAges 18 years+ - NCT06800469Recruiting
Gut bacteria study in pancreatic cancer surgery patients
This trial looks at gut bacteria in people having surgery for pancreatic cancer. It aims to understand how these bacteria might affect recovery or treatment outcomes.
Bologna, BOAges 18 years+ - NCT06801899Recruiting
Total vs. partial Whipple for high-risk pancreatic cancer
This trial compares removing the entire pancreas (total pancreatectomy) versus removing only the head (standard Whipple) for certain cancers of the pancreas, bile duct, or ampulla. It is for people whose surgeon thinks the pancreas connection after surgery is likely to leak, which can cause serious complications.
MünsterAges 18 years+ - NCT06816823RecruitingPhase 1
CAR-NK Cells for Advanced Pancreatic Cancer
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
ShanghaiAges 18–70 - NCT06822413Recruiting
Using light and AI to find cancer early
This trial uses a special light-based test and artificial intelligence to detect several types of cancer early. It aims to see if this method can accurately identify cancer or precancerous changes before any treatment starts.
Nanchang, JiangxiAges Any age
Hear when a new Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatitis?
- Yes. Clin2 currently lists 1,044 recruiting pancreatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.